Medicines Act 1968

Medicines Act 1968

The Medicines Act 1968 is a significant piece of legislation in the United Kingdom that governs the control of medicines for human use and veterinary use. It establishes the legal framework for the manufacture, supply, and sale of medicines, ensuring that they meet standards of safety, quality, and efficacy. The Act was a response to the thalidomide tragedy, which highlighted the need for stricter regulation of pharmaceuticals.

Background

Prior to the Medicines Act 1968, the regulation of medicines in the UK was relatively limited. The thalidomide disaster, where a drug intended for pregnant women to combat morning sickness led to thousands of babies being born with severe birth defects, underscored the urgent need for comprehensive legislation. The Act aimed to prevent such tragedies from occurring in the future by establishing a robust regulatory framework.

Key Provisions

The Medicines Act 1968 introduced several key provisions to regulate medicines, including:

• Licensing of Medicinal Products: No medicinal product can be sold or supplied in the UK without a license granted by the regulatory authority. This ensures that all medicines meet standards of safety, quality, and efficacy.

• Control of Manufacture: The Act requires that the manufacture of medicinal products must be conducted in licensed premises, adhering to strict standards.

• Advertising: The Act imposes restrictions on the advertising of medicinal products, particularly prescription-only medicines, to ensure that advertisements are not misleading.

• Classification of Medicines: Medicines are classified into different categories, such as prescription-only medicines (POM), pharmacy medicines (P), and general sales list (GSL) medicines, based on their safety profile and the need for professional supervision.

• Pharmacovigilance: The Act introduced measures for the monitoring of drug safety, known as pharmacovigilance, to detect, assess, understand, and prevent adverse effects or any other drug-related problems.

Regulatory Authority

The Medicines Act 1968 established the Medicines and Healthcare products Regulatory Agency (MHRA) as the regulatory authority responsible for the enforcement of the Act. The MHRA is tasked with ensuring that all medicines on the UK market meet the required standards of safety, quality, and efficacy.

Impact

The Medicines Act 1968 has had a profound impact on the regulation of medicines in the UK. It has provided a framework for the safe and effective use of medicines, protecting public health and ensuring that the benefits of medicines outweigh their risks. The Act has also facilitated the development of the pharmaceutical industry by providing clear guidelines for the approval and marketing of new medicines.

Amendments and Updates

Over the years, the Medicines Act 1968 has been amended and updated to adapt to scientific advancements and changes in the regulatory landscape. Notable amendments include the introduction of regulations for herbal medicines and the incorporation of European Union directives into UK law.

See Also

• Pharmaceutical industry in the United Kingdom
• Clinical trial
• Drug safety
• Pharmacovigilance

References

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian